research use only
Cat.No.S9555
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Microtubule Associated Inhibitors | Nocodazole MMAF Patupilone (Epothilone B) Lexibulin (CYT997) CW069 Combretastatin A4 Epothilone A ABT-751 (E7010) TAI-1 Cucurbitacin B |
| Molecular Weight | 824.96 | Formula | C46H56N4O10 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 57-22-7 | -- | Storage of Stock Solutions |
|
|
|
In vitro |
DMSO
: 100 mg/mL
(121.21 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| In vitro |
This compound, a microtubule-destabilising agent (MDA), inhibits the formation of microtubules and mitosis of the cancer cell, which is a victim of intratumoural metabolic resistance that has no important relevance with neither CYP3A4 nor CYP3A5. |
|---|---|
| In vivo |
This compound shows the regression of the tumour in zebrafish xenografts. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05844670 | Recruiting | Pediatric Cancer |
Moi University|Princess Maxima Center for Pediatric Oncology|Amsterdam UMC location VUmc |
April 20 2023 | Phase 4 |
| NCT04448834 | Withdrawn | B-cell Acute Lymphoblastic Leukemia |
Dorothy Sipkins MD PhD|Amgen|Acrotech Biopharma Inc.|Duke University |
January 2022 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.